European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Cranbury, NJ, May 22, 2017 -- Information on Cornerstone's upcoming presentation at this prestigious industry conference provided below:
WHAT: In partnership with J.P. Morgan, the BioPartnering Conference is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions. Sanjeev Luther, Cornerstone’s Chief Operating Officer, will present information on the Company’s novel Altered Energy Metabolism Directed (AEMD) platform, and will provide an update on Cornerstone’s clinical trial development strategy in the wake of the company’s recent announcement that it has received approval from the FDA to conduct pivotal clinical trials in acute myeloid leukemia and pancreatic cancer.
Interviews with Mr. Luther prior to and during the conference are available upon request.
WHERE: Busch Campus Center, Rutgers University; 604 Bartholomew Road – Piscataway, NJ 08854
WHEN: May 23, 2017, 1:45 PM
CONTACT: Jacob Jonas, 973-438-3716 or [email protected], for more information.
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Cornerstone approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit www.cornerstonepharma.com.
